Drugs that face an important review decision by the US FDA in August 2021!

Compilenewborn

Since the beginning of this year, the U.
S.
FDA has approved a total of 31 innovative drugs, and 4 (Kerendia, fexinidazole, Rezurock, Bylvay) were approved in July, of which:

-Sanofi fexinidazole is the first full oral treatment for the 2 disease stages of Trypanosoma brucei gambia sleeping sickness;

——Alberio's ileal bile acid transporter (IBAT) inhibitor Bylvay is the first drug to treat all subtypes of progressive familial intrahepatic cholestasis (PFIC);

——Bayer Kerendia is the first non-steroidal selective mineralocorticoid receptor antagonist (MRA) that significantly delays the progression of chronic kidney disease and reduces cardiovascular risk in patients with chronic kidney disease and type 2 diabetes;

-Kadmon's ROCK2 inhibitor Rezurock is the first treatment drug for patients with chronic graft-versus-host disease (GVHD) who have failed multiple alternative treatment options
.

Entering August, a number of drugs will usher in an important review decision by the FDA
.

Reference source: Biotech Stocks Facing FDA Decision In August 2021